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Abstract.  A  new protein,  fibulin-2,  was predicted 
from sequence analysis of cDNA clones obtained from 
a mouse fibroblast library.  This protein consists of a 
l195-residue polypeptide preceded by a 26-residue sig- 
nal peptide.  The COOH-terminal region of 787 amino 
acids contained three anaphylatoxin-related  segments 
(domain I),  11 EGF-like repeats (domain II),  10 of 
which had a consensus motif for calcium-binding,  and 
a  ll5-residue globular domain HI. Except for two ad- 
ditional EGF-like repeats,  this COOH-terminal region 
showed 43 % sequence identity with the previously de- 
scribed fibulin-1  (BM-90). The NH2-terminal 408 
residues,  unique to fibulin-2,  showed no sequence ho- 
mology to other known proteins and presumably form 
two additional domains that differ in their cysteine 
content.  Recombinant fibulin-2 was produced and 
secreted by human cell clones as a disulfide-bonded 
trimer.  Rotary shadowing visualized the protein as 
three 40-45 nm long rods which are connected at one 
end in a globe-like structure.  No significant immuno- 
logical cross-reaction could be detected between 
fibulin-1  and fibulin-2.  Production of the fibulin-2 was 
demonstrated by Northern blots and radioimmunoassay 
in fibroblasts but not in several tumor cell lines.  To- 
gether with the observation that the serum level of 
fibulin-2 is  1,000-fold lower than that of fibulin-1,  the 
data indicate that these two isoforms are not always 
coordinately expressed.  This is also suggested by 
Northern blots of tissue mRNAs and by immunofluo- 
rescence localizations using mouse tissues.  The latter 
studies also demonstrated an extracellular localization 
for fibulin-2 in basement membranes and other con- 
nective tissue compartments. 
M 
OST extracellular matrix proteins have mosaic struc- 
tures  (Bork,  1991; Engel,  1993) and frequently 
possess '~ 50-residue repeats homologous to EGF. 
These repeats usually contain three or, as with laminin  and 
perlecan, four disulfide  bridges stabilizing  a tightly  folded 
structure (Baron et al.,  1991; Selander-Sunnerhagen  et al., 
1992).  As  shown  for laminin  (Beck et al.,  1990;  Engel, 
1993) and tenascin  (Spring  et al.,  1989),  such repeats can 
form rodlike structures  if they occur in multiple consecutive 
copies, and thus may serve as structural or spacing elements. 
An additional  function is their binding of calcium, indicated 
by a special sequence motif identified so far in more than 150 
EGF-like repeats (Rees et al., 1988; Handford et al.,  1991; 
Selander-Sunnerhagen  et  al.,  1992),  This  consensus  se- 
quence has for example been found in the basement mem- 
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brahe proteins nidogen (Mann et al., 1989) and fibulin/BM- 
90 (Argraves et al., 1990; Pan et al., 1993), and is especially 
abundant  in the microfibrillar  protein fibrillin  (Lee et al., 
1991; Maslen et al., 1991). Studies with coagulation  factors 
have shown that  calcium-binding  alSnities  of such repeats 
are in the millimolar  range (Rees et al., 1988; Persson et al., 
1989; Handford et al., 1990), suggesting that modulation of 
binding  can occur in the extracellular  space.  Of particular 
interest,  although  less well studied,  is the participation  of 
EGF-like repeats in the interactions with extracellular  matrix 
proteins and cellular receptors. This was shown for a single 
repeat of the larninin B2 chain which binds nidogen (Mayer 
et al., 1993) while other repeats may be responsible for lami- 
nin's mitogenic activity (Panayotou et al., 1989). The biolog- 
ical  relevance  of these structures  has  been emphasized  by 
mutations  found  in  fibrillin  that  cause Marfan  syndrome 
(Dietz et al., 1991, 1992; Lee et al., 1991) and mutations in 
the neurogenic  Drosophila protein notch  which are lethal 
(Kelley et al.,  1987). 
Recent cDNA  sequence analysis  of human  and  mouse 
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that the major central domain of the protein consists of nine 
EGF-like repeats,  with eight of them possessing the con- 
sensus sequence for calcium binding. This protein was origi- 
nally  described  as  integrin-binding  fibulin  from  human 
placenta (Argraves  et al., 1989) and as BM-90 from a base- 
ment  membrane-producing  mouse  tumor  (Kluge  et  al., 
1990).  Preliminary electronmicroscopical data suggested a 
rodlike structure for fibulin-1 (Kluge, 1990), consistent with 
the sequence predictions. Calcium binding to fibulin-1 is ap- 
parently required to mediate its binding to laminin and nido- 
gen (Pan et al.,  1993).  Other interactions were observed 
with fibronectin and with fibulin-1 itself but were not depen- 
dent on calcium (Balbona et al.,  1992;  Pan et al.,  1993). 
Little else  is  known about possible  functions except that 
fibulin-1  shows prominent expression at sites of epithelial 
endothelial-mesenchymal transitions during embryonic de- 
velopment (Spence et al.,  1992;  Zhang et al.,  1993). 
In our sequence analysis of mouse fibulin-1  (Pan et al., 
1993), several similar cDNA clones were obtained that sug- 
gested the existence of a second isoform. Completion of the 
sequence of these clones now predicts a novel and longer 
protein, fibulin-2. This also suggests that both isoforms are 
members of a new family of genetically related extracellular 
matrix proteins. Recombinant expression of fibulin-2 dem- 
onstrated its assembly into oligomers consisting of three 
identical subunits, while fibulin-1 consists of  monomers. Ad- 
ditional differences between the fibulin isoforms were noted 
in their expression patterns in cultured cells and tissues, sug- 
gesting that they may have different biological functions. 
Materials and Methods 
Isolation and Sequencing of  cDNA Clones 
A  mouse  fibroblast  eDNA  library  was  prepared  from  5  #g  of poly 
A-enriched RNA using reagents from a  cDNA synthesis kit (Pharmacia 
Inc., Piscataway,  NJ) and a kZAP II cloning kit (Stratagene Inc., La Jolla, 
CA). The unamplified cDNA library ("~5 ×  105 clones) was screened with 
a 650-bp human fibulin-1 cDNA prepared by the polymerase chain reaction 
based on published sequences (Argraves et al., 1990; Pan et al., 1993). The 
screening was performed under low stringency hybridization conditions (6 
× SSC at 55°C) (Sambrook et al., 1989). Several positive clones with insert 
sizes from 1.2 to 4.4 kb were characterized by dideoxynucleotide DNA se- 
quencing (Sanger et al., 1977).  The DNA sequence was compared to se- 
quences in the databank using the FASTA computer program (Pearson and 
Lipman,  1988). 
Northern Blot Analysis 
Total RNA was prepared from mouse fibroblasts using the acid guanidine 
thiocyanate/pbenol/chloroform  extraction procedure (Chomcynski and Sac- 
chi, 1987).  Total RNAs were separated on a 1% agarose gel containing 6% 
formaldehyde and transferred to the Hybond N nylon membrane (Amer- 
sham Corp., Arlington Heights, IL). A Northern blot filter containing poly 
A-rich RNA  from various  mouse tissues was obtained  from Clontech 
Laboratories (Palo Alto, CA). The RNA filters were hybridized with nick- 
translated fibulin-1 (MK24) (Pan et al., 1993),  fibulin-2 (MK9), or human 
actin (American Type Culture Collection, Rockville, MD) cDNA probes 
under stringent conditions as described (Sambrook et al.,  1989). 
Expression Vector, Transfections, and Cell Culture 
A full-length fibulin-2 cDNA clone (MK9, 4,377 bp in pBluescript SK-) was 
linearized at the unique BgII site in the Y-untranslated region of the eDNA 
insert, and then blunt-ended  by filling in using the Klenow fragment of DNA 
polymerase. The cDNA insert was released by digestion with NotI in the 
polylinker of the pBluescript vector. The eukaryotic Rc/CMV expression 
vector (Invitrogen, San Diego, CA) was linearized at the XbaI site in the 
polylinker region, blunt-ended, and then digested with NotI, whose site oc- 
curs 5' to the XbaI site in the polylinker region. The resulting vector was 
ligated with the cDNA insert, yielding an expression plasmid pCMK9 com- 
prising 50 bp of the 5'-untranslated region, 3,663 bp of the entire coding 
region and 370 bp of the 3"untranslated region. 
Human embryonic kidney 293 ceils (American Type Culture Collection) 
were cotransfected with pCMK9 and plasmid pSV2pac in order to generate 
stably transfected cell clones (Nischt et al., 1991). Those clones, which pro- 
duced and secreted fibulin-2, were identified by SDS electrophoresis of 
serum-free culture medium examined under reducing conditions. Serum- 
free culture medium was then prepared on a large scale (0.5-1  liter) by es- 
tablished protocols (Fox et al.,  1991; Nischt et al.,  1991). 
Protein Purification 
Fibulin-2 was precipitated from serum-free culture medium ("~0.5 liter) by 
adding solid ammonium sulfate to 50%  saturation (overnight, 4°C). The 
precipitate was then dissolved in "-5 ml of 0.15 M NaCl, 0.05 M Tris-HCl, 
pH 7.4, containing protease inhibitors and passed over a Sepharose CL-6B 
column (3  x  130  cm) equilibrated in the same buffer (Paulsson et al., 
1987a). Pooled fractions containing the protein were subsequently dialyzed 
against 2 M urea, 0.02 M bis-Tris-propane-HC1, pH 6.5, 5 mM EDTA and 
chromatographed on a Mono Q column (HRS/5;  Pharmacia) which was 
eluted with a linear NaCl gradient (0-0.6 M NaC1, 35 ml) prepared in the 
same buffer.  If a final purification step was required, chromatography on 
a Superose 6 column (HR 16/50; Pharmacia Inc.) in 0.2 M ammonium ace- 
tate, pH 6.8, was used. Samples were dissolved in neutral buffer and stored 
at -20°C. Reduction and alkylation in 6 M guanidine-HCl followed a pro- 
cedure previously reported (Kluge et al.,  1990). 
Fibulin-1  (BM-90) was prepared either from a mouse tumor (Kluge et 
ai., 1990) or obtained as a recombinant product based on eDNA encoding 
the splice variant D (Pan et al., 1993) following a protocol as outlined above 
(Sasaki, T.,  M.-L. Chu, and R. Timpl, unpublished data).  Recombinant 
mouse nidogen (Fox et al., 1991) and human BM-40 (Nischt et al.,  1991) 
were prepared as previously described. Laminin-nidogen complex and the 
beparan-sulfate-proteoglycan perlecan were purified from a mouse tumor 
(Paulsson et al., 1987a and b). Human plasma fibronectin (Behringwerke 
Ag, Marburg Lahn, Germany) and vitronectin (Yatohgo et al., 1988) were 
obtained by chromatography on beparin-Sepharose. 
Analytical Methods and Rotary Shadowing 
PAGE (3-10% gradient gels) in the presence of SDS followed established 
protocols. Runs were calibrated with protein standards used in nonreduced 
or reduced form. Protein samples were hydrolyzed with 6  M HC1 (16 h, 
110°C)  for the determination of amino acid composition and protein con- 
centrations using an LC 3000 analyzer (Biotronik). Amino acid sequences 
were determined by a 473A gas-phase sequencer (Applied Biosystems, Inc., 
Foster City, CA) following the manufacturer's instructions. Rotary shadow- 
ing and EM of proteins followed previously described methods (Paulsson 
et ak,  1987a  and b). 
Immunological Methods 
Immunization of rabbits, ELISA, and radioimmuno-inhibition assays fol- 
lowed standard procedures (Timpl, 1982).  Affinity-purified rabbit antibod- 
ies against mouse fibulin-1 (BM-90) were those described previously (Kluge 
et al., 1990).  Most tissues used for indirect immunofluorescenco were ob- 
tained from a 4-wk-old female BALB/c mouse. The skin specimen was iso- 
lated from the abdominal region of a  1-day-old BALB/c mouse. All tissue 
specimens were frozen by liquid nitrogen and cryosections (°°6/~m) were 
prepared on a Reichert-Jung cryostat (Leica, Inc., Deerfield, IL). Sections 
were fixed in acetone for 10 rain at  -20°C and washed in PBS, pH 7.2. 
Antibodies against fibulin-1 (1:20) and fibulin-2 (1:150) were diluted as indi- 
cated in PBS containing 1% ovalbumin. Normal rabbit serum (1:150) served 
as a  negative control.  Fluorescence labeling was performed with FITC- 
conjugated swine anti-rabbit immunoglobulins (DAKOPATTS,  Copenha- 
gen,  Denmark).  All  the  fluorescent specimens were  mounted  in  10% 
glycerol containing 1 mg/ml B-phenylenediamine (Johnson et al.,  1982). 
Microscopy was  carried out  with a  Axiophot fluorescence microscope 
(Zeiss, Oberkochen, FRG). 
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Cloning and Sequence Analysis of Fibulin-2 
Screening of a mouse fibroblast cDNA library with a human 
fibulin-1  cDNA  probe  under  low  stringency  conditions 
yielded two groups of homologous cDNA clones. One group 
encoded two different splice variants of mouse fibulin-1 (Pan 
et al.,  1993). The second group encoded a larger, novel pro- 
tein referred to in the following discussion as fibulin-2. The 
largest fibulin-2 cDNA clone (MKg, 4.4 kb) was used to de- 
termine the whole nucleotide sequence (Fig.  1). 
The nucleotide sequence of clone MK9 predicted an open 
reading frame of 3,633 bp, 50 bp of Y-untranslated region, 
and 664 bp of 3'-untranslated region (Fig.  1). Applying the 
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Figure 1. Nucleotide sequence of fibniin-2 cDNA clone MK9 and 
deduced amino acid sequence. The signal peptidase cleavage site 
is indicated (~); amino acid numbering starts after this site. Full 
arrow heads denote the beginning and ending of various domains 
and subdomains (see  Fig. 2). Asparagines identified as potential 
N-glycosylation  sites are circled and an RGD sequence is boxed. 
These  sequence  data are available from EMBL/GenBank/DDBJ 
under accession  number X75285. 
(-3, -1) rule (von Heijne,  1985), a 26-residue signal peptide 
and  1195  residues  for the mature protein were  predicted. 
Fibulin-2, therefore, exceeds the size of mouse fibulin-1 vari- 
ant C  (Pan  et  al.,  1993)  by  576  residues.  The  region of 
similarity between the two fibulins is restricted to the 3'-half 
of fibulin-2 (60 % nucleotide identity). The predicted amino 
acid sequence shows that fibulin-2 is rich in cysteine (107 
residues), and contains four N-linked oligosaccharide accep- 
tor sites scattered throughout the molecule (Fig. 1). A single 
RGD sequence (positions 395-397) suggests a cell-adhesive 
site. A highly acidic region (9 Glu, 1 Asp) is found at posi- 
tions 246-255.  A  similar acidic sequence followed later by 
RGD has been described for bone sialoprotein (Oldberg et 
al.,  1988). 
Four smaller fibulin-2 cDNA clones were also partially se- 
quenced.  These  clones  (2.5-3  kb)  showed  a  gap  in  the 
nucleotide  sequence  (positions 2175-2316)  corresponding 
to  the  predicted  subdomain  lly (Fig.  2),  suggesting  a 
modifcation  by  alternative  splicing.  Four  fibulin-1  splice 
variants (A-D) have been described (Argraves et al.,  1990; 
Pan et al., 1993) which differ at their 3' ends and the common 
point of deviation would correspond to nucleotide position 
3669  in  fibulin-2.  The  examination  of 6  fibulin-2  cDNA 
clones encompassing this region, however, did not reveal any 
sequence difference. 
Domain Structure and Comparison with Fibulin-1 
The  fibulin-2  sequence  predicts  a  multidomain  structure 
(Fig.  2).  The NH~-terminal 408  residues  (domain N)  are 
unique  to  fibulin-2  and  show  no  sequence  similarity  to 
fibulin-1 or to any other protein sequence found in the EMBL 
data bank. 22 cysteines are clustered in the frst 150 residues 
of domain N,  which  suggests  that the  whole  structure is 
folded into two different subdomains, Na (Cys-rich) and Nb 
(Cys-free). We could neither detect any compelling internal 
homology  in the cysteine patterns  of domain Na  nor any 
similarity to cysteine arrays  in other proteins. 
The remaining structure of fibulin-2 is much more similar 
N 
o  b 
z:l  I 
I  II  III 
o  b  c  x  Q  y  b  c  d  e  f  g  h  i 
I  II  III 
obc  o  b  cd  e  f  g  h  i 
........  m~  (a5) 
I~  (+17) 
D  ES;~ 037) 
Oomoin  modets  of fibutin I ond Z 
Figure 2. Domain model of fibulin-2 (2) and comparison with that 
of fibulin-1 (1) starting with the NH2 termini at the left side. Dia- 
monds in domain I indicate three motifs related to anaphylatoxins. 
Circles in domain II represent EGF-like repeats and those with a 
dot possess  a consensus  motif for calcium binding. The unique 
globular domain N consists of a Cys-rich (a) and a Cys-free (b) seg- 
ment. The COOH-terminal domain III exists in fibulin-1 in four al- 
ternatives, A-D (amino acid numbers in brackets), while  only a 
homolog to variant C has been detected in fibulin-2. The domain 
model for fibulin-1 is based on previous data (Argraves et ai., 1990; 
Pan et al.,  1993). 
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CCAAGQQ AIDNDE CQEIPENGAQSDI CRIAQRQ  CCISYLKEKS 
TD N M  NQHRD  SLPYTSESKE--  MV E  HNQLE LH 
CVAGVMGAKEGET CGAEDNDT--  CGVSLYKQ CCD 
AT INL S P  G  ASLHSYNSS  LETIFI R  H 
CCGLGLRVRAEGQS CESNPNLGYP  CNHVMLS  CC 
M  KASL RD T  PIVMIS-Q  GL FRA 
CLMLPGEL 
CI~NGP 
RC~3 
CI.~GTtlD 
CVTDLItT 
I  GSHN 
CVT THN 
E  I 
CTSI.~EP 
•  r.  "rSA 
Ia 
Ib 
Ic 
Domain II 
IIx  DQDE 
IIa  QPNT 
LNDR 
IIy  DQDE 
IIb  DINE 
IIc  DVDE 
I 
IId  DINE 
IIe  DVNE 
D 
IIf  DVNE 
I 
IIg  DVNE 
IIh  DIDE 
IIi  DLDE 
I 
Domain III 
*  * *  ***  *  .  *  * 
CQHL  CINTVGSYR CA  CFPGFELQGDGRT  CR 
CRQV  CRWGDTAM  CS  CFPGYAIMADGVS  CE 
K Q  DT  EVI  V  QLQS 
CSWKQF CVNTLGSFY CVNHTVL CAEGYILNAHRK  CV 
CTRA~H CVNTPGSFQ CYKALT  CEPGYVLTDGE-  CT 
RLGES  I  V  R  QRDSS  GT  EL EDNN  K 
CQAGFS CQNTKGSFY CQARQR  CMDGFLQDPEGN  CV 
PPDFI  L  R  RPKLQ  KS  I  AL  I 
CRSGFS CINTVGSYT CQRNPLV CGRGYHANEEGSE  CV 
PV QT  E  K VPN  L  TR 
CETGVHR  CGEGQL CYNLPGSYR CD 
APPAEP  K HH  L  S  F  E 
CWVSPGRL  CQHT  CENTPGSYR CS 
QRY  G K  FH 
CETRR  CSQE  CANIYGSYQ CY 
LNSP  V 
CAQGAGIL- CTFR  CVNVPGSyQ CA 
LPT GHI  SY  I  I  F  S 
CALGTHN  CSEAET CHNIQGSFR CLRFD 
VT  IN  F  S E 
CKPGFQRDAFGRT  CI 
A  YF GIS  V 
CAAGFLLAADGKH  CE 
S  R SV  RS 
CRQGYQLAE  -DGHT CT 
R  SDV  V  E 
CPEQGYTMMANGRS CK 
SS  RLAP  N  Q 
CpPNYVRVSQTK  CE 
E  RSAD  R  A 
RTTCQDI  TECQTSPARI  THYQLNFQTGLLVPAH  I  FRI  GPAPAFAGDT  I  SLTITKGNEEGYFV 
LP HENQ  PRLPLS  Y H  S P NIQ  VV  M  SS VP  SMQ A  A  F  T 
TRRLNAYTGVVSLQRSVLE  PRDFALDVEMKLWRQGSVTT  FLAKMY  I  FFTT  FAP  -COOH 
KVSHHS  A  TKPIP  LL T K D  Y H T  SS V  LF  VSAEL-COOH 
Figure 3. Sequence alignment of similar repeats in domains I and 
II of  fibulin-2 and comparison with the sequence of  mouse fibulin-1. 
The assignment of repeats is correlated to those in Figs. 1 and 2 
and include in addition the  single copy of domain HI.  The se- 
quences shown on top are from fibulin-2 with substitutions found 
in fibulin-1 indicated underneath. Dashes indicate gaps introduced 
for optimal alignment of  the two fibulin sequences. Asterisks on top 
of domain I and II sequences indicate residues conserved in most 
of the repeats, including several conservative substitutions. They 
include all residues considered to be essential for calcium ligation 
in domain II, except for the repeat IIa. 
Sunnerhagen et ai.,  1992), and all belong to the type II con- 
sensus motif (Handford et ai.,  1991). 
Sequence comparison of  those domains shared by fibulin-1 
and -2 (Fig. 3) showed a low identity of 26% for domain I 
and required several gaps to be introduced for cysteine align- 
ment. Identity was increased to 55 % in domain II with all 
the cysteines and residues required as calcium ligands being 
conserved. Domain l/I showed 43 % identity when compared 
to fibulin-1  variant C but no similarity to the corresponding 
variants B and D (see Fig. 2). In addition, comparison of the 
link regions failed to show any similarity. Taken together, the 
average identity is 43 % for those regions common to both 
fibulin isoforms (666 residues). 
Recombinant Expression of  Fibulin-2 
Several stable 293 cell clones were obtained after transfec- 
tion with full-length fibulin-2 cDNA in an expression vector 
containing transcriptional control regions of  the human cyto- 
megalovirus. These 293-cei1 clones showed a single band in 
Northern blots  similar  in  size  to  that  of fibroblasts,  and 
which was not detectable in the parent 293 cells. Examina- 
tion of serum-free cell culture medium by SDS electrophore- 
sis under reducing conditions revealed a  major ,x,200-kD 
band unique to those clones and, occasionally, some smaller 
degradation products that blotted with an antiserum against 
fibulin-2 (data not shown).  These findings were confirmed 
by radioimmunoassay of the media obtained from various 
clones  (see  below),  which  demonstrated  1-18  /zg/ml  of 
fibulin-2. Less than 0.02/zg/ml was detected in 293 cells. 
A single clone (MK9-41) which showed high production 
and minimal degradation was used for large scale purifica- 
tion of fibulin-2. After molecular sieve chromatography of 
ammonium sulfate-precipitated material, the protein eluted 
in  a  distinct  peak  shortly  after  the  void  volume  of  a 
Sepharose CL-6B column. Some fibulin-2 was also detected 
in  a  peak  emerging  with  the  void volume and  probably 
represents small amounts of aggregated protein. Fibulin-2 of 
>95 %  electrophoretic homogeneity was  then obtained by 
Mono Q anion exchange chromatography, where the protein 
eluted in a broad range of the NaCI gradient (0.4-0.5 M). 
Reduced fibulin-2 consists of a single electrophoretic band 
with an apparent molecular mass of 195 kD (Fig. 4, lane 3). 
A major single band >400 kD was observed prior to reduc- 
tion (Fig. 4, lane/) indicating that fibulin-2 is secreted in the 
to fibulind  (Fig. 2), including domain I, which consists of 
three 35-residue motifs with a regular pattern of six cysteines 
similar to that of anaphylatoxins (Belt et al.,  1984; Wetsel 
et al., 1984, 1987; de Bruijn and Fey, 1985). Because subdo- 
main  Ib  lacks  one cysteine and  two are missing  in  Ib  of 
fibulin-1  (Fig.  3),  the  same  disulfide bridge as  suggested 
from the structure of anaphylatoxin C3a (Huber et al., 1980) 
would be eliminated in both cases.  Domain I is connected 
by a 50-residue link to the first EGF-like repeat IIx of  domain 
II and is followed after another link (34 residues) by 10 more 
EGF-like repeats (IIa-i, y) and the COOH-terminal domain 
III. All these structures, except the repeats IIx and IIy and 
the first link, have homologous counterparts in fibulin-1.  10 
of the  EGF-like repeats  of fibulin-2  (Fig.  3)  possess  the 
consensus sequence DX(D/N)ECXnCXnCXNX(F/Y)XC, in- 
dicating a calcium binding site (Rees et al.,  1988;  Selander- 
Figure 4. Electrophoresis pat- 
tern of recombinant fibulin-2 
in comparison to recombinant 
fibulin-1. Samples used were 
recombinant  fibulin-2 (lanes 
1  and  3)  and  recombinant 
fibulin-1 (lanes 2 and 4). They 
were  analyzed  under  non- 
reducing conditions  (lanes 1 
and  2)  or  after  reduction 
(lanes  3  and  4).  Runs were 
calibrated  with  nonreduced 
(left margin) or reduced (fight 
margin)  globular  proteins 
with migration position indi- 
cated  by  their  molecular 
masses (kD). 
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consists of a  single 85-kD band which shifts to a  105-kD 
migration position after reduction (Fig. 4, lanes 2 and 4) as 
previously observed for tissue-derived forms of the protein 
(Argraves et al.,  1989; Kluge et al.,  1990). 
In addition to the major 200-kD band, several other clones 
showed  a  distinct  160-kD  band,  which  in  some  purified 
batches, even predominated. Several more distinct although 
minor bands (100-140 kD) could be detected occasionally 
and may have arisen during purification. These smaller vari- 
ants were also connected into oligomers by disulfide bonds. 
Because these smaller fibulin-2 variants cannot be the prod- 
ucts of mRNA splicing, they must have been generated by 
endogenous proteolysis. 
Structural and Immunological Properties 
Edman degradation of the fibulin-2  195-kD band demon- 
strated  the  NH:-terminal  sequence  VPWQDXTGA,  in 
agreement with the signal peptidase cleavage site predicted 
from the cDNA sequence (Fig.  1). Finding the same NH2- 
terminal sequence as was found for the 160-kD band would 
indicate that proteolytic shortening starts from the COOH- 
terminal end. Rotary shadowing of disulfide-bonded fibulin-2 
revealed particles of low contrast showing a  characteristic 
three arm structure composed of  thin rods (Fig. 5). The aver- 
age length of the rods was 40-45 nm, but smaller rods were 
also noted which could represent artifacts of degradation or 
could reflect imperfect metal  decoration.  The connecting 
structure frequently appears as a globular domain. Smaller 
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Figure 6.  ELISA binding profiles of antisera against fibulin-1 and 
-2.  The antibodies used were an antiserum against recombinant 
fibulin-2  (o,  zx)  and  affinity-purified antibodies  against tissue- 
derived fibulin-1 (e, A). They were titrated against recombinant 
fibulin-2 (o, e) and recombinant fibulin-1 (zx, A). 
globular structures were seen occasionally at the free ends 
of the  strands.  We  interpret  this  major  structure  as  an 
oligomer of three fibulin-2 chains in which only a  limited 
portion of the chains are required for association. Other par- 
ticles of fibulin-2 appeared as dimers or tetramers,  or oc- 
curred in large aggregates with an undefined structure. 
A  rabbit  antiserum  was  raised  against  fibulin-2  which 
showed in ELISA a high titer for fibulin-2 and a  1,000-fold 
lower binding to fibulin-1 (Fig. 6). A similar low binding was 
observed for recombinant nidogen but no reaction occurred 
Figure 5. Visualization of individual particles of fibulin-2 by rotary 
shadowing. Note a frequent characteristic three-arm structure. 
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Figure  7.  Analysis  of  fibulin-2  and  biological  samples  by 
radioimmuno-inhibition assay. The test consisted of fixed concen- 
trations  of antiserum to  fibulin-2  and  125I-labeled fibulin-2.  Pu- 
rified  protein  inhibitors  used  at various  concentrations  (bottom 
scale, ng/rrd) were recombinant fibulin-2 (o), fibulin-1 (D), and re- 
duced and alky]ated fibulin-2 (e). Biological fluids used as inhibi- 
tots were culture medium from fibulin-2 clone MKg-2]  (zx), pa- 
rental  293  cells  (&),  fibroblasts  (~,),  b9  cells  (v),  and normal 
mouse serum (I).  The amounts (in #l) added to 0.2 ml inhibitor 
solution are shown on the top scale. 
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tin,  or vitronectin.  In contrast,  antisera or affinity-purified 
antibodies against tissue-derived fibulin-1  (Fig. 6) showed a 
distinct reaction with recombinant fibulin-1  but no reaction 
with fibulin-2. This suggests that the antisera should be able 
to differentiate between the two isoforms of fibulin in com- 
plex biological specimens. 
In addition,  the antiserum against fibulin-2 showed high 
titer in radioimmunoassay, allowing us to establish a sensi- 
tive inhibition test (IC50 =  4 ng/ml) for the quantitative de- 
termination of the antigen (Fig.  7).  Inhibition profiles with 
identical slopes produced by fibulin-2 and culture medium 
from fibulin-2 clones and fibroblasts indicate that the anti- 
gens present in the biological samples share the same epi- 
topes  (Timpl,  1982).  Mouse  serum,  however,  was only a 
weak inhibitor,  indicating a  fibulin-2 concentration of less 
than 20  ng/ml.  The inhibition  assay was  specific because 
fibulin-1,  even at 1,000-fold excess, showed no activity. The 
inhibitory activity of reduced and alkylated fibulin-2 was de- 
creased to low levels indicating that most of the epitopes in- 
volved depend on an intact conformation. 
Expression and Localization  of the Fibulin Isoforms 
in Tissues 
Initial  studies  were  performed  with  cultured  cells  using 
Northern  blots  and  radioimmunoassay  determinations  of 
proteins secreted in the culture medium (Fig. 7).  Fibulin-2 
was detected in four different mouse fibroblast media at an 
average concentration of 260  +  130 ng/ml but was not de- 
tected in the medium of mouse teratocarcinoma cell line F9, 
parietal endoderm cells PYS-2, and B16F10 melanoma cells 
(<20  ng/ml).  Northern  blot  analysis  of total  RNA  from 
mouse fibroblasts showed hybridization to a broad band at 
the position of 28S ribosomal RNA (Fig. 8 A). This is consis- 
tent with the existence of at least two different mRNA tran- 
scripts due to the presence or absence of a single EGF-like 
repeat (fly). Fibulin-2 mRNA was not expressed in F9 ceils 
(data not shown) in contrast to the previous observation for 
fibulin-1  (Pan et al.,  1993). 
The expression of fibulin-2 was also examined by North- 
ern  blotting  using  poly  A-rich  RNA  from  various  adult 
mouse tissues (Fig. 8 B). The fibulin-2 probe detected a 4.5- 
kb mRNA, in good agreement with the size of the full-length 
eDNA. However, the eDNA also detected another transcript 
of ,07.0 kb in some tissues. It is not clear whether or not the 
7.0-kb band is transcribed from the same gene. The strongest 
hybridization was observed in heart tissue and much weaker 
signals were found in lung,  liver,  skeletal muscle, kidney, 
brain,  spleen, and testis tissue.  It was noted the 7-kb tran- 
script was stronger than the 4.5-kb band in kidney and brain 
tissue.  The tissue expression pattern was compared to that 
of fibulin-1  (Fig. 8 B) which is characterized by 2.3- and 2.7- 
kb transcripts (Argraves et al., 1990; Pan et al.,  1993). Both 
fibulin-1  and -2 mRNAs were present at very high levels in 
heart tissue.  However, more fibulin-1  mRNA than fibulin-2 
mRNA was found in lung,  testis, kidney, and brain tissue. 
A  comparative study of the tissue localization of the two 
isoforms of fibulin was performed by indirect immunofluo- 
rescence.  Identical  staining  patterns  were  observed  for 
skeletal muscle and heart tissue outlining the extracellular 
space that surrounds the muscle fibers (Fig. 9 a  and b).  In 
the cornea, both fibulin-1  and fibulin-2 are found along Bow- 
man's and  Descemet's membrane (Fig.  9  c).  Staining  for 
fibulin-1  was strong in the stromal compartment. In contrast, 
strong deposits of fibulin-2 could be detected in the squa- 
mous epithelium on top of Bowman's membrane, while only 
little staining was found in the stroma. Kidney tissue con- 
Figure 8. Northern blots of RNA 
from mouse  fibroblasts  and  tis- 
sues.  (,4) 10  /zg  of total  RNA 
from  mouse  fibroblasts  was 
probed with fibulin-2 eDNA clone 
MK9. (B) Northern blot analysis 
of  poly  A-enriched RNAs from 
mouse tissues.  Each lane  con- 
tained 2 ~g of  poly  A-enriched 
RNA and was probed sequentially 
with fibulin-2 eDNA (MK9), fibu- 
lin-1 eDNA (MK24) (Pan et al., 
1993), and human actin eDNA. 
The Journal of Cell Biology, Volume 123, 1993  1274 Figure 9.  Immunofluorescence staining pattern of various mouse tissues by antisera specific for fibulin isoforms. Staining in row 1 was 
with affinity-purified  anti-fibulin-1 and in row 2 with anti-fibulin-2. Two consecutive tissue sections are illustrated under a-f:  (a) Skeletal 
muscle, (b) heart muscle, (c) cornea with Descement's membrane on the left, (d) kidney showing a single glomerulus, (e) aorta in cross 
section, (f) skin with the epidermis on top and the subcutis starting at the bottom region. Similar tissue sections were also incubated 
with normal rabbit serum which yielded negative results except for a very weak staining of the epidermis (data not shown). Bars, 40 #m. 
tained  both isoforms of fibulin as  illustrated  for a  single 
glomerulus in Fig. 9 d. Both antisera showed strong staining 
of the mesangium.  The antiserum against fibulin-1  showed 
a distinct reaction with the glomerular loops (Fig. 9 d), and 
a weak staining of tubular basement membranes (not shown). 
The  latter  observation  was  confirmed previously by  im- 
munogold staining  (Kluge,  1990).  Examination of kidney 
sections at low magnification demonstrated a strong reaction 
for fibulin-2 but not for fibulin-1  in the wall of small vessels. 
A  similar  difference was  observed  for aorta  with  strong 
staining for fibulin-2 in the subintimal layer and very faint 
reactions in the media and adventitia (Fig. 9 e). No signifi- 
cant staining of aorta could be observed for fibulin-1.  Simi- 
larly, fibulin-2, but not fibulin-1,  could be detected around 
portal veins in the liver, while no staining was observed in 
the perisinusoidal  space (not shown).  The strongest reac- 
tions for fibulin-2 were observed in the skin including the 
epidermal cell layer, the dermis, and the adipose tissue in the 
subcutis (Fig. 9f). A distinct staining was also seen around 
the glassy membranes and the keratinocytes of hair follicles. 
Staining for fibulin-1  was also distinct but mainly restricted 
to the glassy membranes,  the epidermal-dermal junction, 
and some dermal structures underneath this junction which 
could represent small capillaries. 
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Sequence analysis, recombinant expression, and immuno- 
logical assays demonstrate that fibulin-2 is a new extracellu- 
lar matrix protein. The closest relative seems to be fibulin-1, 
with 43 % sequence identity between the domains shared by 
the two proteins. This level of identity is in the range ob- 
served for other protein isoforms like the diverse laminin 
chains, which also contain multiple EGF-like repeats (En- 
gel,  1993).  We suggest classification of the fibulins into a 
novel protein family and suggest use of arabic numbers for 
their distinction as used with the thrombospondins (Born- 
stein, 1992).  Many consecutive EGF-like repeats with cal- 
cium-binding motifs are the hallmark of fibrillin (lee et al., 
1991; Maslen et al., 1991) and TGF-/31 binding protein (Kan- 
zaki et al., 1990) but are less abundant in nidogen (Mann et 
al., 1989) and EGF precursor (Scott et al., 1983). The multi- 
ple repeats in these proteins, however, are joined to domains 
different  from those found in the fibulins. In addition, several 
Drosophila and Caenorhabditis elegans  proteins (notch, lin- 
12, and others) contain tandem arranged EGF-like repeats 
and play a role in development (Kelley et al., 1987; Yochem 
and Greenwald, 1989; Bork, 1991). The common structural 
motifs suggest that these proteins may have originated from 
common ancestral precursors by exon shuffling and together 
represent a superfamily. 
EM of recombinant fibulin-2 demonstrates a trimeric rod 
structure connected by disulfide bonds. A similar structure 
but with large, calcium~ependent globular domain~ at the 
distal ends was described for thrombospondin-1 (Lawler et 
al., 1985).  The two proteins show only a low similarity in 
sequence and domain structure (Lawler and Hynes, 1986). 
It is not presently known whether or not other isoforms of 
thrombospondin (Bornstein, 1992) have similar structures. 
In contrast, fibulin-1 has the shape of a single rod of '~, 30 
nm length (Kluge, 1990).  The rods of fibulin-2 are longer 
(40-45 nm) and very likely include the 11 EGF-like repeats 
of domain II. The predicted length for a row of such repeats 
is about 25 um (Engel, 1989), suggesting that other domains 
(Nb, I and HI) are included in the rod structure. The reduced 
chain of fibulin-2 and a truncated 160-kD form share the 
same NH2-terminal sequence, thus indicating that domain 
Na contributes the disulfide bonds for the connection of the 
rods and is part of the central globular domain. A disulfide- 
linked NH2-terminal connection has also been identified for 
thrombospondin-1. 
The molecular mass of the fibulin-2 chain, based on the 
sequence and assuming substitutions with typical N-linked 
oligosaccharides, was calculated to be ~142 kD. The mass 
determined from electrophoretic migration, however,  was 
195 kD. A similar difference between calculated (82 kD) and 
observed (105 kD) molecular mass was found for fibulin-1, 
indicating either substitution with unusually large oligosac- 
charides, or an anomalous electrophoretic mobility common 
to beth fibulins, which should be further studied by ultracen- 
trifugation.  Calcium  binding  has  been  shown  only  for 
fibulin-1 (Argraves et al., 1990; Kluge et al., 1990), but the 
number  of occupied sites  and their affinities are  not yet 
known. The binding of fibulinq to laminin or nidogen is de- 
pendent on calcium and completely abolished by EDTA (Pan 
et al., 1993). Preliminary studies with fibulin-2 show that its 
binding to fibronectin and some other ligands is also calcium 
dependent (Sasaki, T., and R. Timpl, unpublished results), 
suggesting that some of the putative calcium-binding motifs 
in domain II of fibulin-2 are active in providing calcium 
coordination sites. 
A  low immunological cross-reactivity was observed be- 
tween the two fibulins which is presumably accounted for by 
the relatively low sequence identity and further differences 
in the domain structure. This allows us to differentiate the 
two proteins by radioimmnno- and other immunological as- 
says in various biological samples. The serum concentration 
of fibulin-2 is low and comparable with those of most other 
extracellular matrix proteins fRisteli and Risteli, 1987).  A 
serum concentration at  at  least  1,000-fold  higher (20-30 
#g/ml) has been found for fibnlin-1 (Argraves et al.,  1990; 
Kluge et al., 1990) suggesting different  cellular origins of  the 
circulating fibulin isoforms. We have shown by Northern 
blots that liver cells are an unlikely source of serum fibulin-1, 
although hepatocytes  are  the  main  producers  of  serum 
fibronectin (Hynes, 1990). 
Fibroblasts are the only cells examined so far that produce 
both  isoforms of fibulins as  shown in this and previous 
studies (Argraves et al., 1990; Kluge et al., 1990). Fibulin-2 
was not detected by radioimmunoassay in several mouse tu- 
mor  cell  lines,  but  a  substantial  secretion  of fibulin-1 
(100-460  ng/ml) was observed (Kluge et al.,  1990).  An 
overlapping, but not identical, tissue expression pattern of 
both fibulins was also observed by Northern analyses of 
RNAs from cultured ceils and tissues. It appears that the ex- 
pression of fibnlin-2 is more restricted, and the regulation of 
the expression of  the two fibulin isoforms is not strictly coor- 
dinated. Of particular interest is the high expression of both 
fibulin mRNAs in heart tissue. Fibulin-1 has been shown to 
be enriched in the endocardial cushion tissue during heart 
development (Spence et al., 1992; Zhang et al., 1993). The 
expression of fibulin-2 in developing heart tissue remains to 
be investigated. 
Differences are noted in the tissue localiTation of the two 
fibulins by indirect immunoflnorescence. Fibulin-2, but not 
fibulin-1,  is detected in the keratinocyte cell layer of the 
epidermis and hairs, the epithelial cell layer of cornea, the 
aortic intima, and around small vessels in kidney and liver. 
However,  staining of fibulin-1  seems to be much stronger 
than fibulin-2 in the corneal stroma and glomerular base- 
ment membranes. Both isoforms colocalize in several other 
anatomical compartments such as the perimysium of skeletal 
muscle, the matrix surrounding myocytes, the renal mesan- 
gium, and the two basement membranes of the cornea, but 
the latter interpretation still needs confirmation by immuno 
electronmicroscopy.  Together  the  data  demonstrate  that 
fibulin-2 is a typical extraceUular matrix protein, which can 
be a component of  both basement membranes and other con- 
nective tissues. 
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